These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 10352922)

  • 21. Male PCOS equivalent and nutritional restriction: Are we stepping forward?
    Di Guardo F; Cerana MC; D'urso G; Genovese F; Palumbo M
    Med Hypotheses; 2019 May; 126():1-3. PubMed ID: 31010486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Tapanainen JS
    Hum Reprod; 2000 Jun; 15(6):1266-74. PubMed ID: 10831553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
    Nardo LG; Patchava S; Laing I
    Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.
    Dunaif A; Xia J; Book CB; Schenker E; Tang Z
    J Clin Invest; 1995 Aug; 96(2):801-10. PubMed ID: 7635975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgens in polycystic ovary syndrome: the role of exercise and diet.
    Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
    Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
    De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
    Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of polycystic ovary syndrome: involvement of genetic and environmental factors.
    Franks S; McCarthy MI; Hardy K
    Int J Androl; 2006 Feb; 29(1):278-85; discussion 286-90. PubMed ID: 16390494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperandrogenaemia and the ovary.
    Norman RJ
    Mol Cell Endocrinol; 2002 May; 191(1):113-9. PubMed ID: 12044925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives.
    Colilla S; Cox NJ; Ehrmann DA
    J Clin Endocrinol Metab; 2001 May; 86(5):2027-31. PubMed ID: 11344202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome.
    Dhindsa G; Bhatia R; Dhindsa M; Bhatia V
    J Postgrad Med; 2004; 50(2):140-4. PubMed ID: 15235215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
    Ortiz-Flores AE; Luque-Ramírez M; Escobar-Morreale HF
    Expert Opin Pharmacother; 2018 Dec; 19(17):1915-1926. PubMed ID: 30289728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of diagnosing the polycystic ovary syndrome.
    Lobo RA; Carmina E
    Ann Intern Med; 2000 Jun; 132(12):989-93. PubMed ID: 10858183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity.
    Ciaraldi TP
    J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1291-3. PubMed ID: 11117672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Polycystic ovary syndrome: a disorder of insulin action and an increased risk for onset of non-insulin-dependent diabetes].
    Aganović I; Jelcić J; Kozić-Rukavina B
    Lijec Vjesn; 1996 Mar; 118 Suppl 1():28-32. PubMed ID: 8759405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin resistance, polycystic ovary syndrome and metformin.
    Pugeat M; Ducluzeau PH
    Drugs; 1999; 58 Suppl 1():41-6; discussion 75-82. PubMed ID: 10576524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCOS and diabetes mellitus: from insulin resistance to altered beta pancreatic function, a link in evolution.
    Condorelli RA; Calogero AE; Di Mauro M; La Vignera S
    Gynecol Endocrinol; 2017 Sep; 33(9):665-667. PubMed ID: 28644709
    [No Abstract]   [Full Text] [Related]  

  • 38. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome.
    Lewy VD; Danadian K; Witchel SF; Arslanian S
    J Pediatr; 2001 Jan; 138(1):38-44. PubMed ID: 11148510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose intolerance in the polycystic ovary syndrome: role of the pancreatic beta-cell.
    Ehrmann DA
    J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1299-301. PubMed ID: 11117674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.